U.S. Markets close in 2 hrs 56 mins
  • S&P 500

    3,855.41
    -44.70 (-1.15%)
     
  • Dow 30

    31,199.38
    -238.88 (-0.76%)
     
  • Nasdaq

    11,299.61
    -224.95 (-1.95%)
     
  • Russell 2000

    1,762.75
    -9.00 (-0.51%)
     
  • Crude Oil

    111.83
    +2.26 (+2.06%)
     
  • Gold

    1,822.70
    -2.10 (-0.12%)
     
  • Silver

    20.84
    -0.32 (-1.53%)
     
  • EUR/USD

    1.0523
    -0.0063 (-0.5998%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.36
    +0.41 (+1.52%)
     
  • GBP/USD

    1.2187
    -0.0084 (-0.6812%)
     
  • USD/JPY

    136.2190
    +0.7730 (+0.5707%)
     
  • BTC-USD

    20,701.07
    -45.09 (-0.22%)
     
  • CMC Crypto 200

    450.27
    +0.21 (+0.05%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    27,049.47
    +178.17 (+0.66%)
     

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Biogen Inc. (NASDAQ: BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ: KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended.

  • As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen.

  • KPTI received an upfront payment of $10 million in 2018 and was eligible to receive additional payments of up to $207 million based on the achievement by Biogen of future specified development and commercial milestones.

  • KPTI was also eligible to receive tiered royalty payments that reach low double-digits based on future net sales.

  • Due to the termination of the agreement, Karyopharm is now not entitled to any milestone payments or royalties. However, it has certain rights relating to the purchased assets upon termination of the agreement.

  • Price Action: KPTI shares are trading lower by 3.74% at $4.38 during the post-market session on Wednesday, and BIIB closed higher by 1.59% at $197.26.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.